The complex relationship of serum adiponectin to COPD outcomes

Ho Il Yoon, Yuexin Li, S. F Paul Man, Donald Tashkin, Robert A Wise, John E. Connett, Nicholas A. Anthonisen, Andrew Churg, Joanne L. Wright, Don D. Sin

Research output: Contribution to journalArticle

Abstract

Background: COPD is a chronic inflammatory disorder with high risk of cardiovascular morbidity and mortality. Adiponectin is a hormone that has antiinflammatory, antidiabetic, and antiatherogenic activities. We investigated the relationship of serum adiponectin to health outcomes in COPD. Methods: We measured adiponectin levels in serum samples from participants of the Lung Health Study, who were smokers with mild to moderate airflow limitation. We determined the relationship of serum adiponectin to hospitalization and mortality using a Cox proportional hazards model and to baseline lung function measurements and bronchial reactivity using multiple regression methods. Results: Serum adiponectin concentrations were inversely related to hospitalizations and mortality from coronary heart disease (hazard ratio [HR], 0.73; 95% CI, 0.62-0.86) and to cardiovascular disease (HR, 0.83; 95% CI, 0.73-0.94) and positively related to deaths from respiratory causes (HR, 2.09; 95% CI, 1.41-3.11). However, serum adiponectin concentrations were not significantly related to total mortality (HR, 1.10; 95% CI, 0.93-1.29) or cancer-related mortality (HR, 1.11; 95% CI, 0.92-1.34). Serum adiponectin concentrations were significantly related to increased bronchial reactivity and an accelerated decline in lung function (both P <.0001). Smoking status had no material influence on serum adiponectin concentrations. Conclusions: Adiponectin is a complex serum biomarker in COPD that is associated with decreased risk of cardiovascular events but increased risk of respiratory mortality. Because serum adiponectin is not significantly influenced by smoking status, it is a very promising biomarker of cardiovascular outcomes in COPD.

Original languageEnglish (US)
Pages (from-to)893-899
Number of pages7
JournalChest
Volume142
Issue number4
DOIs
StatePublished - Oct 2012

Fingerprint

Adiponectin
Chronic Obstructive Pulmonary Disease
Serum
Mortality
Lung
Hospitalization
Biomarkers
Smoking
Health
Proportional Hazards Models
Hypoglycemic Agents
Coronary Disease
Cause of Death
Anti-Inflammatory Agents
Cardiovascular Diseases
Hormones
Morbidity

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Yoon, H. I., Li, Y., Man, S. F. P., Tashkin, D., Wise, R. A., Connett, J. E., ... Sin, D. D. (2012). The complex relationship of serum adiponectin to COPD outcomes. Chest, 142(4), 893-899. https://doi.org/10.1378/chest.11-2173

The complex relationship of serum adiponectin to COPD outcomes. / Yoon, Ho Il; Li, Yuexin; Man, S. F Paul; Tashkin, Donald; Wise, Robert A; Connett, John E.; Anthonisen, Nicholas A.; Churg, Andrew; Wright, Joanne L.; Sin, Don D.

In: Chest, Vol. 142, No. 4, 10.2012, p. 893-899.

Research output: Contribution to journalArticle

Yoon, HI, Li, Y, Man, SFP, Tashkin, D, Wise, RA, Connett, JE, Anthonisen, NA, Churg, A, Wright, JL & Sin, DD 2012, 'The complex relationship of serum adiponectin to COPD outcomes', Chest, vol. 142, no. 4, pp. 893-899. https://doi.org/10.1378/chest.11-2173
Yoon HI, Li Y, Man SFP, Tashkin D, Wise RA, Connett JE et al. The complex relationship of serum adiponectin to COPD outcomes. Chest. 2012 Oct;142(4):893-899. https://doi.org/10.1378/chest.11-2173
Yoon, Ho Il ; Li, Yuexin ; Man, S. F Paul ; Tashkin, Donald ; Wise, Robert A ; Connett, John E. ; Anthonisen, Nicholas A. ; Churg, Andrew ; Wright, Joanne L. ; Sin, Don D. / The complex relationship of serum adiponectin to COPD outcomes. In: Chest. 2012 ; Vol. 142, No. 4. pp. 893-899.
@article{3fb6789f38f44b29b79a5dab019dafc6,
title = "The complex relationship of serum adiponectin to COPD outcomes",
abstract = "Background: COPD is a chronic inflammatory disorder with high risk of cardiovascular morbidity and mortality. Adiponectin is a hormone that has antiinflammatory, antidiabetic, and antiatherogenic activities. We investigated the relationship of serum adiponectin to health outcomes in COPD. Methods: We measured adiponectin levels in serum samples from participants of the Lung Health Study, who were smokers with mild to moderate airflow limitation. We determined the relationship of serum adiponectin to hospitalization and mortality using a Cox proportional hazards model and to baseline lung function measurements and bronchial reactivity using multiple regression methods. Results: Serum adiponectin concentrations were inversely related to hospitalizations and mortality from coronary heart disease (hazard ratio [HR], 0.73; 95{\%} CI, 0.62-0.86) and to cardiovascular disease (HR, 0.83; 95{\%} CI, 0.73-0.94) and positively related to deaths from respiratory causes (HR, 2.09; 95{\%} CI, 1.41-3.11). However, serum adiponectin concentrations were not significantly related to total mortality (HR, 1.10; 95{\%} CI, 0.93-1.29) or cancer-related mortality (HR, 1.11; 95{\%} CI, 0.92-1.34). Serum adiponectin concentrations were significantly related to increased bronchial reactivity and an accelerated decline in lung function (both P <.0001). Smoking status had no material influence on serum adiponectin concentrations. Conclusions: Adiponectin is a complex serum biomarker in COPD that is associated with decreased risk of cardiovascular events but increased risk of respiratory mortality. Because serum adiponectin is not significantly influenced by smoking status, it is a very promising biomarker of cardiovascular outcomes in COPD.",
author = "Yoon, {Ho Il} and Yuexin Li and Man, {S. F Paul} and Donald Tashkin and Wise, {Robert A} and Connett, {John E.} and Anthonisen, {Nicholas A.} and Andrew Churg and Wright, {Joanne L.} and Sin, {Don D.}",
year = "2012",
month = "10",
doi = "10.1378/chest.11-2173",
language = "English (US)",
volume = "142",
pages = "893--899",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "4",

}

TY - JOUR

T1 - The complex relationship of serum adiponectin to COPD outcomes

AU - Yoon, Ho Il

AU - Li, Yuexin

AU - Man, S. F Paul

AU - Tashkin, Donald

AU - Wise, Robert A

AU - Connett, John E.

AU - Anthonisen, Nicholas A.

AU - Churg, Andrew

AU - Wright, Joanne L.

AU - Sin, Don D.

PY - 2012/10

Y1 - 2012/10

N2 - Background: COPD is a chronic inflammatory disorder with high risk of cardiovascular morbidity and mortality. Adiponectin is a hormone that has antiinflammatory, antidiabetic, and antiatherogenic activities. We investigated the relationship of serum adiponectin to health outcomes in COPD. Methods: We measured adiponectin levels in serum samples from participants of the Lung Health Study, who were smokers with mild to moderate airflow limitation. We determined the relationship of serum adiponectin to hospitalization and mortality using a Cox proportional hazards model and to baseline lung function measurements and bronchial reactivity using multiple regression methods. Results: Serum adiponectin concentrations were inversely related to hospitalizations and mortality from coronary heart disease (hazard ratio [HR], 0.73; 95% CI, 0.62-0.86) and to cardiovascular disease (HR, 0.83; 95% CI, 0.73-0.94) and positively related to deaths from respiratory causes (HR, 2.09; 95% CI, 1.41-3.11). However, serum adiponectin concentrations were not significantly related to total mortality (HR, 1.10; 95% CI, 0.93-1.29) or cancer-related mortality (HR, 1.11; 95% CI, 0.92-1.34). Serum adiponectin concentrations were significantly related to increased bronchial reactivity and an accelerated decline in lung function (both P <.0001). Smoking status had no material influence on serum adiponectin concentrations. Conclusions: Adiponectin is a complex serum biomarker in COPD that is associated with decreased risk of cardiovascular events but increased risk of respiratory mortality. Because serum adiponectin is not significantly influenced by smoking status, it is a very promising biomarker of cardiovascular outcomes in COPD.

AB - Background: COPD is a chronic inflammatory disorder with high risk of cardiovascular morbidity and mortality. Adiponectin is a hormone that has antiinflammatory, antidiabetic, and antiatherogenic activities. We investigated the relationship of serum adiponectin to health outcomes in COPD. Methods: We measured adiponectin levels in serum samples from participants of the Lung Health Study, who were smokers with mild to moderate airflow limitation. We determined the relationship of serum adiponectin to hospitalization and mortality using a Cox proportional hazards model and to baseline lung function measurements and bronchial reactivity using multiple regression methods. Results: Serum adiponectin concentrations were inversely related to hospitalizations and mortality from coronary heart disease (hazard ratio [HR], 0.73; 95% CI, 0.62-0.86) and to cardiovascular disease (HR, 0.83; 95% CI, 0.73-0.94) and positively related to deaths from respiratory causes (HR, 2.09; 95% CI, 1.41-3.11). However, serum adiponectin concentrations were not significantly related to total mortality (HR, 1.10; 95% CI, 0.93-1.29) or cancer-related mortality (HR, 1.11; 95% CI, 0.92-1.34). Serum adiponectin concentrations were significantly related to increased bronchial reactivity and an accelerated decline in lung function (both P <.0001). Smoking status had no material influence on serum adiponectin concentrations. Conclusions: Adiponectin is a complex serum biomarker in COPD that is associated with decreased risk of cardiovascular events but increased risk of respiratory mortality. Because serum adiponectin is not significantly influenced by smoking status, it is a very promising biomarker of cardiovascular outcomes in COPD.

UR - http://www.scopus.com/inward/record.url?scp=84867129700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867129700&partnerID=8YFLogxK

U2 - 10.1378/chest.11-2173

DO - 10.1378/chest.11-2173

M3 - Article

C2 - 22207678

AN - SCOPUS:84867129700

VL - 142

SP - 893

EP - 899

JO - Chest

JF - Chest

SN - 0012-3692

IS - 4

ER -